Clinical application of PCI-32765 for the treatment of B cell malignancies / 国际肿瘤学杂志

ABSTRACT

PCI-32765,an oral selective and irreversible inhibitor of Bruton tyrosine kinase (BTK),inhibits survival,activation,proliferation and migration of malignant B cells by blocking B cell receptor signaling pathway.PCI-32765 not only acts on malignant B cell,but also prevents resistance to chemical drugs.Therefore,PCI-32765 has broad prospects in the treatment of B cell malignancies.